ReviewFrontiers in pharmacology2017
Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Metabolome Profiling of Yokukansan in Preventing Postoperative Delirium in Elderly Cancer Patients: A Reverse Translational Study.Psychiatry and clinical neurosciences · 2025Trial
- Randomized double-blind placebo-controlled multicenter trial for the effects of a polyherbal remedy, Yokukansan (YiganSan), in smokers with depressive tendencies.BMC complementary medicine and therapies · 2022Trial
- Trial
- Potential pharmacological quality control markers in the traditional Japanese medicine Hangeshashinto: identifying anti-inflammatory ingredients through a cell-based bioassay and multicomponent analysis.Pharmaceutical biology · 2025Article
- The Antiviral Effect of Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, on Murine Coronavirus Growth in the Lung and Liver of Infected Mice.Microorganisms · 2025Article
- Serotonin-Mediated Anti-Allodynic Effect of Yokukansan on Diabetes-Induced Neuropathic Pain.Journal of clinical medicine · 2024Article
- The Serotonin-Mediated Anti-Allodynic Effect of Yokukansan on Paclitaxel-Induced Neuropathic Pain.Medicina (Kaunas, Lithuania) · 2024Article
- Protective Effects of 18β-Glycyrrhetinic Acid on Neonatal Rats with Hyperoxia Exposure.Inflammation · 2022Article
- Brain distribution of geissoschizine methyl ether in rats using mass spectrometry imaging analysis.Scientific reports · 2020Article
- Kampo Medicine for Various Aging-Related Symptoms: A Review of Geriatric Syndrome.Frontiers in nutrition · 2020Review
- Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.PloS one · 2020Article
- Effectiveness of the traditional Japanese Kampo medicine Yokukansan for chronic migraine: A case report.Medicine · 2019Article
- Analyses of the possible anti-tumor effect of yokukansan.Journal of natural medicines · 2019Article
- Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan.Molecules (Basel, Switzerland) · 2018Article
- Potential Application of Yokukansan as a Remedy for Parkinson's Disease.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Traditional Japanese Herbal Medicine Yokukansan Targets Distinct but Overlapping Mechanisms in Aged Mice and in the 5xFAD Mouse Model of Alzheimer's Disease.Frontiers in aging neuroscience · 2018Article
- Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells.Frontiers in pharmacology · 2017Review
- Excessive daytime sleepiness in adolescents: current treatment strategies.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yokukansan (YKS), a traditional Japanese Kampo medicine, has indications for use in night crying and irritability in children, as well as neurosis and insomnia. It is currently also used for the remedy of the behavioral and psychological symptoms of dementia (BPSD), such as aggressiveness, agitation, and hallucinations. In parallel with clinical evidence, a significant amount of fundamental researches have been undertaken to clarify the neuropsychopharmacological efficacies of YKS, with approximately 70 articles, including our own, being published to date. Recently, we reviewed the neuropharmacological mechanisms of YKS, including its effects on glutamatergic, serotonergic, and dopaminergic neurotransmission, and pharmacokinetics of the ingredients responsible for the effects. This review is aimed to integrate the information regarding the psychopharmacological effects of YKS with the brain regions known to be affected, to facilitate our understanding of the clinical efficacy of YKS. In this review, we first show that YKS has several effects that act to improve symptoms that are similar to BPSDs, like aggressiveness, hallucinations, anxiety, and sleep disturbance, as well as symptoms like tardive dyskinesia and cognitive deficits. We next provide the evidence showing that YKS can interact with various brain regions, including the cerebral cortex, hippocampus, striatum, and spinal cord, dysfunctions of which are related to psychiatric symptoms, cognitive deficits, abnormal behaviors, and dysesthesia. In addition, the major active ingredients of YKS, geissoschizine methyl ether and 18β-glycyrrhetinic acid, are shown to predominantly bind to the frontal cortex and hippocampus, respectively. Our findings suggest that YKS has multiple psychopharmacological effects, and that these are probably mediated by interactions among several brain regions. In this review, we summarize the available information about the valuable effects of a multicomponent medicine YKS on complex neural networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.